Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ
Open Access
- 6 August 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (15) , 3843
Abstract
Despite the wide use of angiotensin II receptor blockers in the treatment of Alport syndrome (AS), the mechanism as to how angiotensin II receptor blockers prevent interstitial fibrosis remains unclear. Here, we report that treatment of olmesartan effectively targets the feedback loop between the renin–angiotensin system (RAS) and transforming growth factor β (TGFβ) signals in tubular epithelial cells and preserves renal angiotensin-converting enzyme 2 (ACE2) expression in the kidney of Col4a3–/– mice, a murine model of experimental AS. Morphology analyses revealed amelioration of kidney fibrosis in Col4a3–/– mice by olmesartan treatment. Upregulation of TGFβ and activation of its downstream in Col4a3–/– mice were attenuated by olmesartan in Col4a3–/– mice. Intriguingly, TGFβ expression was preferentially upregulated in damaged tubular epithelial cells in Col4a3–/– mice. Concurrent upregulation of TNFα-converting enzyme and downregulation of ACE2 suggested RAS activation in Col4a3–/– mice, which was prevented by olmesartan. Mechanistically, olmesartan suppressed TGFβ-induced RAS activation in tubular epithelial cells in vitro. Collectively, we concluded that olmesartan effectively suppresses the progression of tubulointerstitial fibrosis in AS by interrupting RAS-TGFβ feedback loop to counterbalance intrarenal RAS activation.Keywords
This publication has 34 references indexed in Scilit:
- Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane NephropathyJournal of the American Society of Nephrology, 2013
- Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndromePediatric Nephrology, 2012
- Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosisNephrology Dialysis Transplantation, 2004
- Alport's Syndrome, Goodpasture's Syndrome, and Type IV CollagenNew England Journal of Medicine, 2003
- Laminin-1 reexpression in Alport mouse glomerular basement membranes11See Editorial by Miner, p. 1158.Kidney International, 2003
- Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome11See Editorial by Abbate and Remuzzi, p. 764.Kidney International, 2003
- Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related CarboxypeptidaseJournal of Biological Chemistry, 2002
- Type IV Collagen of the Glomerular Basement MembraneJournal of Biological Chemistry, 2000
- Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.Journal of Clinical Investigation, 1997
- Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.Genes & Development, 1996